Business Context and Reporting Period
This Form 8-K Current Report, dated April 8, 2005, details the completion of Illumina, Inc.'s acquisition of CyVera Corporation, a developer of digital microbead technology. The report also discloses a material employment agreement entered into in connection with the merger.
Key Financial Metrics and Transaction Details
- Acquisition Consideration: Illumina issued approximately 1.6 million shares of common stock and paid approximately $2.5 million in cash (including assumed liabilities).
- Contingent Consideration: Up to 250,000 additional shares (Escrow Shares) may be issued to former CyVera stockholders, held in escrow until April 8, 2006.
- Executive Compensation: Alan Kersey, Ph.D., was appointed Vice President and Site General Manager of CyVera with an annual base salary of $220,000.
- Equity Grants: Dr. Kersey received two stock options:
- Option 1: 100,000 shares at $8.52/share, vesting over five years.
- Option 2: 100,000 shares at $8.52/share, vesting over 12 months starting April 8, 2014, unless milestones are met earlier.
Note: This filing does not provide consolidated revenue, profit, cash flow, or margin data for Illumina, Inc.
Material Changes
The primary material change is the consolidation of CyVera Corporation as a wholly-owned subsidiary of Illumina. Illumina assumed CyVera's outstanding stock options and certain liabilities. The transaction involved the issuance of unregistered equity securities pursuant to Section 4(2) of the Securities Act of 1933.
Outlook, Risks, and Contingencies
- Future Filings: Audited financial statements for CyVera and pro forma financial information will be filed via amendment within 71 calendar days of this report.
- Registration: Illumina will file a registration statement within 45 days to register the Shares and Escrow Shares for resale.
- Change of Control: The Second Option granted to Dr. Kersey includes an acceleration clause for 50% of shares if a change of control occurs and the milestone plan is cancelled or modified.
Key Facts for Investor Verification
- Verify the total value of the acquisition by calculating the market value of the 1.6 million shares issued plus the $2.5 million cash payment.
- Monitor the upcoming amendment to this 8-K for CyVera's audited financial statements and pro forma impact on Illumina's balance sheet.
- Confirm the vesting schedule and milestone requirements for the 250,000 Escrow Shares and Dr. Kersey's Second Option.
- Review the registration statement to be filed within 45 days regarding the resale of the newly issued shares.